Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Dec 31, 2025
Revenue increased in the current quarter compared to the prior quarter and also rose versus the same quarter one year earlier. All quarterly comparisons used available data only.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue increased in the current quarter compared to the prior quarter and also rose versus the same quarter one year earlier. All quarterly comparisons used available data only.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.2B
Revenue reported for this quarter.
Quarter-over-quarter
+3.7%
Change from the immediately preceding quarter.
Year-over-year
+9.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$12B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $2.8B | +3.0% |
| Jun 30, 2025 | $3B | +12.1% |
| Sep 30, 2025 | $3.1B | +11.0% |
| Dec 31, 2025 | $3.2B | +9.5% |
Revenue performance
Reported revenue for the quarter was higher than the three months ended June and September of the same year, continuing an upward trajectory seen across the periods in the supplied trend. The annual total reached a level above the sum of the first three quarters.
Quarterly comparison
Revenue in the current quarter exceeded the immediately preceding quarter and also outpaced the same quarter one year earlier by a larger margin than the sequential gain. The trailing twelve-month figure was notably above the current quarter's standalone amount.
What to watch
No forward-looking guidance or specific segment breakdown was provided in the filing context; monitor upcoming disclosures for operational drivers.